Camlin Fine Sciences Limited (CAMLINFINE) AI Stock Analysis

• Market Cap: ₹36.92B
• Dividend Yield: N/A
• Average Volume (3M): 39.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: 8.06%
• EPS Growth: 19.90%
• Country: IN
• Employees: 624
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): 0.20
• Shares Outstanding: 187,980,440
• 10 Day Avg. Volume: 26,894
• 30 Day Avg. Volume: 39,045
• PEG Ratio: -0.48
• Price to Book (P/B): 3.33
• Price to Sales (P/S): 1.80
• P/FCF Ratio: -190.82
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: ₹215.00 ▲(9.81% Upside)

Camlin Fine Sciences Limited's overall stock score is primarily impacted by its financial performance, which shows revenue growth but significant profitability and cash flow challenges. Technical analysis indicates a bearish trend, and valuation concerns arise from a negative P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.

Camlin Fine Sciences Limited Business Overview & Revenue Model

Company Description

Camlin Fine Sciences Limited (CAMLINFINE) is a leading global provider of specialty chemicals, focusing on the food, pharmaceuticals, and agrochemical sectors. The company is engaged in the manufacture and supply of a diverse range of products, including antioxidants, aroma chemicals, and various performance chemicals that enhance the quality and longevity of food and pharmaceutical products. With a strong emphasis on innovation and sustainability, Camlin Fine Sciences aims to deliver high-quality solutions to its customers while addressing global challenges such as food safety and health.

How the Company Makes Money

Camlin Fine Sciences generates revenue primarily through the sale of its specialty chemicals and performance products across various industries. Key revenue streams include the production of antioxidants used in food preservation and pharmaceuticals, aroma chemicals for flavor and fragrance applications, and agrochemical intermediates. The company benefits from long-term contracts with major clients and a diverse customer base, which provides a stable income. Additionally, strategic partnerships with industry leaders and ongoing investment in research and development contribute to its financial growth, allowing Camlin Fine Sciences to innovate and expand its product offerings in response to market demand.

Camlin Fine Sciences Limited Financial Statement Overview

Summary

Camlin Fine Sciences Limited shows modest revenue growth but faces significant profitability challenges with negative net profit margins and net income. The balance sheet is stable with moderate leverage, but cash flow constraints are evident, impacting overall financial health.

Income Statement

The revenue growth over the last year was modest at 4.48%. However, the company has struggled with profitability, as indicated by a negative net profit margin of -8.34% for the latest year. This marks a deterioration from the previous year's margin, which was also negative. Gross profit margins have improved slightly, but overall profitability remains weak, evidenced by negative net income for the past two years.

Balance Sheet

The debt-to-equity ratio is approximately 0.76, indicating a moderate level of leverage. Return on equity has turned negative due to the recent net losses, which is concerning. However, the equity ratio is relatively strong at 44.53%, providing some asset coverage. The balance sheet indicates stability in the asset base but highlights challenges in profitability.

Cash Flow

Operating cash flow has significantly decreased from the previous year. Free cash flow has turned negative, reflecting challenges in generating cash relative to capital expenditures. The operating cash flow to net income ratio is positive, suggesting operational activities are still generating cash, but the free cash flow to net income ratio is negative, highlighting cash constraints.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	16.94B	16.67B	15.95B	16.82B	14.04B	11.81B
Gross Profit	8.97B	7.78B	6.58B	8.41B	6.34B	5.77B
EBITDA	2.54B	1.95B	487.60M	1.84B	1.79B	1.89B
Net Income	-1.15B	-1.39B	-927.53M	521.06M	606.78M	509.63M
Balance Sheet
Total Assets	0.00	20.24B	19.52B	20.60B	18.00B	14.82B
Cash, Cash Equivalents and Short-Term Investments	1.42B	1.92B	812.28M	951.90M	1.29B	1.21B
Total Debt	0.00	6.81B	6.83B	8.01B	6.46B	5.50B
Total Liabilities	-8.75B	11.49B	10.95B	12.36B	10.35B	7.68B
Stockholders Equity	8.75B	9.02B	8.65B	8.19B	7.48B	6.43B
Cash Flow
Free Cash Flow	0.00	-157.24M	784.06M	-934.11M	-683.40M	335.07M
Operating Cash Flow	0.00	267.23M	1.39B	508.98M	1.45B	1.17B
Investing Cash Flow	0.00	-753.50M	-664.98M	-1.25B	-2.49B	-1.33B
Financing Cash Flow	0.00	724.43M	-859.72M	596.58M	1.36B	386.27M

Camlin Fine Sciences Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 195.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAMLINFINE, the sentiment is Neutral. The current price of 195.8 is above the 20-day moving average (MA) of 194.55, below the 50-day MA of 205.27, and below the 200-day MA of 206.09, indicating a neutral trend. The MACD of -3.10 indicates Negative momentum. The RSI at 47.47 is Neutral, neither overbought nor oversold. The STOCH value of 35.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:CAMLINFINE.

Camlin Fine Sciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROSSARI	70 Outperform	₹34.78B	25.45	―	0.08%	15.47%	-1.72%
PREMEXPLN	66 Neutral	₹33.40B	90.93	―	0.09%	62.92%	33.94%
ADVENZYMES	65 Neutral	₹35.12B	25.64	―	1.67%	5.89%	-1.30%
BALAMINES	65 Neutral	₹45.54B	29.91	―	0.79%	-12.28%	-22.10%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
NEOGEN	55 Neutral	₹38.85B	115.48	―	0.07%	11.14%	-11.15%
CAMLINFINE	46 Neutral	₹36.92B	-29.50	―	―	8.06%	19.90%

Camlin Fine Sciences Limited Corporate Events

Camlin Fine Sciences Secures Shareholder Approval for Equity Issuance

Camlin Fine Sciences Limited announced the successful passage of a special resolution through a postal ballot, which involved the issuance of equity shares on a preferential basis as part of a share swap arrangement. The resolution received overwhelming support from shareholders, with a significant majority voting in favor, indicating strong backing for the company’s strategic financial decisions. This move is likely to impact the company’s capital structure and could enhance its market positioning by facilitating strategic partnerships or acquisitions.

Camlin Fine Sciences Corrects Financial Reporting Discrepancy

Camlin Fine Sciences Limited, a company involved in the production of specialty chemicals, submitted its financial results for the quarter and year ended March 31, 2025, to the National Stock Exchange of India. The company addressed a discrepancy in the financial results submitted in XBRL format, which differed from the PDF version. This discrepancy has been corrected, and the revised financial results were filed on July 9, 2025, ensuring compliance with SEBI regulations.

Camlin Fine Sciences Announces Postal Ballot and E-voting Notice

Camlin Fine Sciences Limited has announced the publication of a notice regarding a Postal Ballot and Remote E-voting process in newspapers, as part of its compliance with SEBI regulations. This announcement indicates the company’s commitment to regulatory transparency and shareholder engagement, potentially impacting its corporate governance practices and stakeholder relations.